Company · Biotech and pharma
Non-hormonal therapies for menopausal symptoms
Every investor coverage indicates participated in a round QUEoncologyHealthier menopause treatments raised.
Investors whose own portfolio pages list QUEoncologyHealthier menopause treatments, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Stoic Venture Capital | its portfolio page ↗ |
| Stoic Venture Capital | its portfolio page ↗ |
Companies QUEoncologyHealthier menopause treatments acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Chris Nave | Chairman | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Dr Rob Crombie | Chief Executive Officer | Brandon BioCatalyst portfolio (Thu 1 Aug 2019), Brandon BioCatalyst portfolio (Tue 2 Apr 2019) |
Stories naming QUEoncologyHealthier menopause treatments. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
QUE Oncology reports its non-hormonal drug Q-122 eased hot flushes in breast cancer patients on endocrine therapy, with Phase II results in The Lancet; the Emory–UniQuest venture is backed by Brandon BioCatalyst and Uniseed.
Brandon Capital's blog covers QUE Oncology's Phase II Q-122 results in The Lancet, showing reduced hot flushes and night sweats in breast cancer patients on endocrine therapy.
QUE Oncology expands its Phase II trial of Q-122, a therapy for hot flushes in breast cancer patients on endocrine therapy, to New Zealand sites, with trials also running in Australia and the United States.
QUE Oncology is beginning placebo-controlled Phase II trials of its drug Q-122 at US hospitals, testing it against hot flashes in breast cancer patients on endocrine therapy, with its CEO and a lead investigator quoted.